Abridge announced that Northwestern Medicine is implementing Abridge enterprise-wide across its hospitals and care settings. The announcement appeared in Abridge’s release about unveiling its unified healthcare intelligence platform.

Abridge announced an enterprise-wide agreement with University of Texas REAL Health AI to expand access to its clinician intelligence platform across the University of Texas System. The arrangement establishes a systemwide access framework while retaining local decision-making and implementation.

Abridge was selected to provide ambient AI through a distribution partner under the U.S. Department of Veterans Affairs’ enterprise contract, enabling VA medical centers and regions nationwide to offer its technology to clinicians. The five-year, multi-award contract has a total ceiling of $775.72 million across all vendors eligible to compete for task orders; this is not an Abridge-specific award.

Abridge said it welcomed the team behind Altrina, describing the addition as an investment in people and expertise for its next chapter. The announcement describes the team joining Abridge, not a purchase of Altrina or individual leadership appointments.

WashU Medicine and BJC Health expanded Abridge across BJC Health’s East Region, giving approximately 4,000 clinicians access to the platform after an initial 450-clinician rollout in 2025. The expansion followed an evaluation showing documentation-time reductions that increased with usage, including a 20% reduction in after-hours documentation by day 150.

Abridge announced that partner health systems can extend its context-aware clinical intelligence agent to every clinician in their organizations. The announcement makes the capability available broadly across participating partner health systems rather than limiting it to a subset of clinicians.

Inventurus Knowledge Solutions’ wholly owned subsidiary, IKS Inc., agreed to sell 54,055 Series A-1 preferred shares of Abridge to Alpha Square Group Fund IV, LP, for $10,000,175. Abridge was a confirming party to the stock purchase agreement, and IKS retained a remaining interest in the company.

CHRISTUS Health expanded its relationship with Abridge through an unlimited enterprise agreement, extending the platform across inpatient care and launching a nursing documentation pilot.

Eli Lilly made a strategic investment in Abridge to support evidence-based care and research access. Abridge also announced expanded capabilities connecting clinical conversations with payer, life-science, and clinical-trial workflows; the investment amount was not disclosed.

Abridge expanded its clinical decision-support capabilities through a partnership with Wolters Kluwer’s UpToDate and additional content integrations.

Abridge and Availity began developing real-time prior-authorization workflows that use shared clinical context from patient conversations to support administrative processes and improve payer-provider coordination.